ArisInfra, supported by PharmEasy, is set to launch its INR 500 Cr IPO, marking a significant step in its growth trajectory. This move highlights the strong backing and potential synergies within the PharmEasy network, offering new opportunities for investors.
The B2B ecommerce sector is buzzing with anticipation as ArisInfra, a construction material procurement platform backed by PharmEasy Unlisted Shares, prepares to launch its Initial Public Offering (IPO) to raise approximately INR 500 Cr from the public markets. This development underscores the close ties and strategic advantages that ArisInfra derives from its association with PharmEasy, potentially making it an attractive prospect for investors looking at the unlisted shares market.
ArisInfra's IPO, consisting solely of a fresh issue component, aims to raise INR 499.6 Cr. This follows the company's filing of its red herring prospectus (RHP) after receiving SEBI’s green light nearly seven months prior. Initially, the draft red herring prospectus (DRHP) filed in August 2024 had proposed raising INR 600 Cr, which was later revised to INR 579.6 Cr. Additionally, ArisInfra secured INR 80 Cr in a pre-IPO placement round earlier in the year, issuing equity shares to investors like Vanaja Sundar Iyer and Mukul Mahavir Agrawal.
The IPO is scheduled to open for subscription on June 18 and close on June 20, with shares expected to debut on the BSE and NSE. The proceeds from the IPO are earmarked for strategic purposes, including repaying debt, meeting working capital needs, and investing in its subsidiary, Buildmex-Infra Pvt Ltd. A portion of the funds is also reserved for general corporate purposes and potential inorganic acquisitions.
Founded in 2021 by Ronak Morbia and Bhavik Khara, ArisInfra operates as a B2B construction material procurement platform, supplying essential building materials to real estate and infrastructure developers. Its client roster includes notable names such as The Wadhwa Group, ACC, Piramal Realty, Tata Projects, and JSW Cements. The company's chairman and MD, Ronak Morbia, is supported by PharmEasy founder Siddharth Shah and his family office, with Shah’s family trust, Aspire Family Trust, being the largest shareholder.
Recent financial performance indicates a positive trajectory for ArisInfra. The company turned profitable in the nine months of FY25, reporting a profit of INR 6.5 Cr compared to a loss of INR 17.3 Cr in FY24. The operating revenue for the same period stood at INR 557.8 Cr, although it was slightly lower than the INR 702.4 Cr reported in FY24. This turnaround and sustained revenue generation further solidify the company’s position in the competitive construction material market.
For PharmEasy Unlisted Shares holders and potential investors, ArisInfra's IPO represents an opportunity to witness value creation within the PharmEasy ecosystem. The success of ArisInfra could positively reflect on PharmEasy, demonstrating effective diversification and strategic investment decisions.
Looking ahead, ArisInfra's management, led by ex-Wadhwa Group COO Srinivasan Gopalan, aims to leverage the IPO proceeds to strengthen its market position, expand its service offerings, and pursue strategic acquisitions. This proactive approach signals a promising future for the company and could translate into enhanced returns for stakeholders. As ArisInfra embarks on this new chapter, investors will keenly observe its performance and contribution to the broader PharmEasy narrative, indicating a resilient and forward-thinking approach in a dynamic market.
